KLK3 and prostate carcinoma: This study identified a robust panel of clinically accessible biomarkers—PSA, Index %, hemoglobin (HGB), age, neutrophils, NLR, and IIEF—with significant potential for stratifying patients with prostate cancer (PCa), benign prostatic hyperplasia (BPH), and precancerous lesions (PL).